Form 13-F position report

LEGEND BIOTECH CORP

Reported by HHLR ADVISORS LTD

Company profile Manager portfolio Source filing
LEGN CUSIP 52490G102 Manager CIK 0001762304
Latest reported change

Reported 6,436,533 shares, up 1,306,166 (25.5%) from the prior quarter.

Reported value 79.6%; share count 25.5% vs. the prior quarter.

Added
% of reported 13F value 9.46% This manager · Q2 2023
Shares 6,436,533 Quarter-end amount reported
Reported value $444,313,873 Fair value at quarter end
Consecutive quarters held 13 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Unchanged 5,984,550 0 (0.0%) 20.77% $172,833,804 2026-08-14
Q1 2026 Unchanged 5,984,550 0 (0.0%) 6.47% $108,260,510 2026-05-15
Q4 2025 Unchanged 5,984,550 0 (0.0%) 4.19% $130,104,117 2026-02-17
Q3 2025 Unchanged 5,984,550 0 (0.0%) 4.77% $195,156,176 2025-11-14
Q2 2025 Unchanged 5,984,550 0 (0.0%) 6.84% $212,391,680 2025-08-14
Q1 2025 Unchanged 5,984,550 0 (0.0%) 5.74% $203,055,782 2025-05-15
Q4 2024 Reduced 5,984,550 -651,946 (-9.8%) 6.74% $194,737,257 2025-02-14
Q3 2024 Unchanged 6,636,496 0 (0.0%) 7.1% $323,396,450 2024-11-14
Q2 2024 Added 6,636,496 +651,946 (10.9%) 7.25% $293,930,408 2024-08-14
Q1 2024 Unchanged 5,984,550 0 (0.0%) 7.29% $335,673,410 2024-05-14
Q4 2023 Reduced 5,984,550 -451,983 (-7.0%) 7.26% $360,090,374 2024-02-14
Q3 2023 Unchanged 6,436,533 0 (0.0%) 9.65% $432,341,922 2023-11-14
Q2 2023 Added 6,436,533 +1,306,166 (25.5%) 9.46% $444,313,873 2023-08-14
Q1 2023 Reduced 5,130,367 -6,250 (-0.1%) 4.39% $247,386,297 2023-05-15
Q4 2022 Unchanged 5,136,617 0 (0.0%) 5.41% $256,419,921 2023-02-14
Q3 2022 Added 5,136,617 +700,000 (15.8%) 5.51% $209,574,000 2022-11-14
Q2 2022 Reduced 4,436,617 -2,500,000 (-36.0%) 5.23% $244,014,000 2022-08-15
Q1 2022 Reduced 6,936,617 -4,868,308 (-41.2%) 5.26% $252,077,000 2022-05-16
Q4 2021 Added 11,804,925 +750,000 (6.8%) 8.5% $550,228,000 2022-02-14
Q3 2021 Added 11,054,925 +10,404,925 (1600.8%) 7.31% $558,937,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

210 managers reported LEGEND BIOTECH CORP for Q2 2023.

Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 17,045,498 +650,821 0.1% $1,176,650,727 13 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 9,031,324 +7,939,175 0.09% $623,434,000 5 qtrs
HHLR ADVISORS LTD This report Added 6,436,533 +1,306,166 9.46% $444,313,873 13 qtrs
RA CAPITAL MANAGEMENT L P Added 6,264,707 +3,828,484 8.16% $432,452,724 4 qtrs
BlackRock Inc Added 4,743,594 +615,641 < 0.01% $327,450,294 13 qtrs
Capital World Investors Reduced 2,387,975 -1,392 0.03% $164,841,914 13 qtrs
FEDERATED HERMES INC Reduced 1,941,516 -397,284 0.33% $134,022,849 13 qtrs
Polar Capital Holdings Plc Reduced 1,872,118 -103,513 0.65% $129,232,306 6 qtrs
Capital International Investors Reduced 1,862,009 -88,675 0.03% $128,534,481 13 qtrs
JANUS HENDERSON GROUP PLC Reduced 1,814,337 -124,754 0.08% $125,248,289 5 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
SPONSORED ADS

Voting authority reported

Sole
0
Shared
6,436,533
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.